PAVmed and Veris Health Complete Private Placement Financing Deal

# PAVmed and Veris Health Complete Private Placement Financing Deal

## Introduction

PAVmed Inc. (Nasdaq: PAVM), a diversified commercial-stage medical technology company, and its digital health subsidiary, Veris Health, have successfully completed a private placement financing deal. This strategic move is expected to provide the necessary capital to advance their innovative healthcare solutions, particularly in the field of digital health and remote patient monitoring.

## Overview of the Private Placement Financing Deal

The private placement financing deal involves the issuance of convertible preferred stock and warrants to institutional and accredited investors. The transaction is designed to strengthen PAVmed’s financial position and support Veris Health’s growth initiatives.

Key highlights of the deal include:

– **Total Capital Raised**: The financing deal secured a significant amount of capital, which will be used to fund ongoing operations and strategic initiatives.
– **Convertible Preferred Stock**: Investors received convertible preferred stock, which can be converted into common shares at a predetermined price.
– **Warrants Issued**: The deal also includes the issuance of warrants, allowing investors to purchase additional shares in the future.

## Purpose and Strategic Importance

The funds raised through this private placement will be primarily used to:

1. **Advance Veris Health’s Digital Health Platform**: Veris Health is focused on developing an advanced digital health platform that integrates remote patient monitoring with artificial intelligence (AI)-driven analytics. The financing will accelerate the commercialization of this platform, particularly in oncology care.
2. **Support Product Development and Expansion**: PAVmed and Veris Health plan to use the capital to enhance their product offerings, expand market reach, and improve operational efficiencies.
3. **Strengthen Financial Stability**: The additional funding will provide greater financial flexibility, allowing PAVmed to execute its long-term growth strategy without immediate reliance on public markets.

## Impact on PAVmed and Veris Health

This financing deal is expected to have a positive impact on both companies by:

– **Enhancing Innovation**: The additional capital will enable further research and development, ensuring that PAVmed and Veris Health remain at the forefront of medical technology advancements.
– **Accelerating Commercialization**: With increased financial resources, Veris Health can expedite the rollout of its digital health solutions, improving patient outcomes and healthcare efficiency.
– **Increasing Investor Confidence**: Successfully securing private placement financing demonstrates strong investor confidence in PAVmed and Veris Health’s business model and future growth potential.

## Conclusion

The completion of this private placement financing deal marks a significant milestone for PAVmed and Veris Health. By securing additional capital, the companies are well-positioned to advance their digital health initiatives, expand their market presence, and drive long-term value for investors and stakeholders. As they continue to innovate and grow, their impact on the healthcare industry is expected to be substantial.

This strategic financing move underscores the growing importance of digital health solutions in modern medicine and highlights PAVmed and Veris Health’s commitment to revolutionizing patient care through technology.